Literature DB >> 11698100

Modulation of transmitter release via presynaptic cannabinoid receptors.

E Schlicker1, M Kathmann.   

Abstract

Cannabis (marijuana) is not only a frequently abused drug but also has the potential for the development of useful agents for the treatment of emesis, anorexia and multiple sclerosis. In this article, the effects of modulation of transmitter release by cannabinoids in both the CNS and the PNS of various species, including humans, will be discussed. Cannabinoids inhibit neurotransmitter release via specific presynaptic cannabinoid CB1 receptors. Studies using either the CB1 receptor antagonist and inverse agonist SR141716 or CB1-receptor-deficient mice suggest that numerous presynaptic cannabinoid receptors are tonically activated by endogenous cannabinoids and/or are constitutively active. CB1-receptor-mediated inhibition of transmitter release might explain, for example, reinforcing properties and memory impairment caused by cannabinoids.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698100     DOI: 10.1016/s0165-6147(00)01805-8

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  156 in total

1.  The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

Authors:  Eleni T Tzavara; Richard J Davis; Kenneth W Perry; Xia Li; Craig Salhoff; Frank P Bymaster; Jeffrey M Witkin; George G Nomikos
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

2.  The interaction between hippocampal GABA-B and cannabinoid receptors upon spatial change and object novelty discrimination memory function.

Authors:  Mohammad Nasehi; Niyousha Alaghmandan-Motlagh; Mohaddeseh Ebrahimi-Ghiri; Mohammad Nami; Mohammad-Reza Zarrindast
Journal:  Psychopharmacology (Berl)       Date:  2017-08-05       Impact factor: 4.530

3.  Statistical Parametric Mapping reveals ligand and region-specific activation of G-proteins by CB1 receptors and non-CB1 sites in the 3D reconstructed mouse brain.

Authors:  P T Nguyen; D E Selley; L J Sim-Selley
Journal:  Neuroimage       Date:  2010-05-06       Impact factor: 6.556

4.  Cannabinoid CB(1) receptor-mediated inhibition of hippocampal acetylcholine release is preserved in aged mice.

Authors:  Agnes Redmer; Markus Kathmann; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

Review 5.  Emerging roles for endocannabinoids in long-term synaptic plasticity.

Authors:  Gregory L Gerdeman; David M Lovinger
Journal:  Br J Pharmacol       Date:  2003-09-22       Impact factor: 8.739

6.  Cannabinoid receptor type 1 antagonism significantly modulates basal and loud noise induced neural and hypothalamic-pituitary-adrenal axis responses in male Sprague-Dawley rats.

Authors:  R J Newsom; C Osterlund; C V Masini; H E Day; R L Spencer; S Campeau
Journal:  Neuroscience       Date:  2011-11-28       Impact factor: 3.590

7.  Colonization with the commensal fungus Candida albicans perturbs the gut-brain axis through dysregulation of endocannabinoid signaling.

Authors:  Laura Markey; Andrew Hooper; Laverne C Melon; Samantha Baglot; Matthew N Hill; Jamie Maguire; Carol A Kumamoto
Journal:  Psychoneuroendocrinology       Date:  2020-07-24       Impact factor: 4.905

8.  Unique effects of compounds active at both cannabinoid and serotonin receptors during stroke.

Authors:  Ming Zhang; Anu Mahadevan; Mukkanti Amere; Hongbo Li; Doina Ganea; Ronald F Tuma
Journal:  Transl Stroke Res       Date:  2012-07-26       Impact factor: 6.829

9.  Effects of oral Δ9-tetrahydrocannabinol on the cerebral processing of olfactory input in healthy non-addicted subjects.

Authors:  Carmen Walter; Bruno G Oertel; Lisa Felden; Ulrike Nöth; Johannes Vermehren; Ralf Deichmann; Jörn Lötsch
Journal:  Eur J Clin Pharmacol       Date:  2017-09-02       Impact factor: 2.953

10.  Lack of CB1 receptors increases noradrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetylcholine release.

Authors:  Eberhard Schlicker; Agnes Redmer; Andre Werner; Markus Kathmann
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.